Lanying Du

SARS-CoV-2 spike protein: a key target for eliciting persistent neutralizing antibodies

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine

Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion

Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses

Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China

An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies

Learning from the past: development of safe and effective COVID-19 vaccines

Neutralizing antibodies for the treatment of COVID-19

Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2

Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement

Therapeutic antibodies and fusion inhibitors targeting the spike protein of SARS-CoV-2

Current development of COVID-19 diagnostics, vaccines and therapeutics

From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development

Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen

Neutralization of Zika virus by germline-like human monoclonal antibodies targeting cryptic epitopes on envelope domain III

Vaccines for the prevention against the threat of MERS-CoV

Cell Entry of Porcine Epidemic Diarrhea Coronavirus Is Activated by Lysosomal Proteases

Two Mutations Were Critical for Bat-to-Human Transmission of Middle East Respiratory Syndrome Coronavirus

Protective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV Infection

Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus

Characterization and Demonstration of the Value of a Lethal Mouse Model of Middle East Respiratory Syndrome Coronavirus Infection and Disease

Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines

Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments—The importance of immunofocusing in subunit vaccine design

Advancements in the development of subunit influenza vaccines

Receptor-binding domain-based subunit vaccines against MERS-CoV

Identification of a Receptor-Binding Domain in the S Protein of the Novel Human Coronavirus Middle East Respiratory Syndrome Coronavirus as an Essential Target for Vaccine Development

A Truncated Receptor-Binding Domain of MERS-CoV Spike Protein Potently Inhibits MERS-CoV Infection and Induces Strong Neutralizing Antibody Responses: Implication for Developing Therapeutics and Vaccines

Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate

Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome

A predicted receptor-binding and critical neutralizing domain in S protein of the novel human coronavirus HCoV-EMC